LPL and fatty liver disease: In parallel with testosterone-associated changes in LXR expression in the present study, we saw alterations in known LXR target genes: Fasn, Apoe, Abca1, Lpl, Srebpf1. Rather than inducing hepatic steatosis as with many LXR agonists, testosterone additionally protects against diet-induced hepatic lipid accumulation in this model [17].